The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

Veale, D. J. et al. (2019) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 58(2), pp. 197-205. (doi: 10.1093/rheumatology/key070) (PMID:29618084) (PMCID:PMC6343466)

Abstract

The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molecular mechanisms of SpA and provide a rationale for JAK inhibition for the treatment of SpA. We also review the available clinical trial data evaluating JAK inhibitors tofacitinib, baricitinib, peficitinib, filgotinib and upadacitinib in PsA, AS and related inflammatory diseases, which have demonstrated the efficacy of these agents across a range of SpA-associated disease manifestations. The available clinical trial data, supported by pre-clinical animal model studies demonstrate that JAK inhibition is a promising therapeutic strategy for the treatment of SpA and may offer the potential for improvements in multiple articular and extra-articular disease manifestations of PsA and AS.

• Item Type: Articles
• Additional Information: This work was funded by Pfizer Inc.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: McInnes, Professor Iain
• Authors: Veale, D. J., McGonagle, D., McInnes, I. B., Krueger, J. G., Ritchlin, C. T., Elewaut, D., Kanik, K. S., Hendrikx, T., Berstein, G., Hodge, J., and Telliez, J.-B.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Research Centre: College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
• Journal Name: Rheumatology
• Publisher: Oxford University Press
• ISSN: 1462-0324
• ISSN (Online): 1462-0332
• Published Online: 03 April 2018
• Copyright Holders: Copyright © 2018 The Authors
• First Published: First published in Rheumatology 58(2): 197-205
• Publisher Policy: Reproduced under a Creative Commons License